道培醫療數據
CAR-T治療
719
非血緣案例
1039
親緣半相同案例
3883
移植案例
5979

陸佩華 /陸道培醫院醫療執行院長、美國血液病及腫瘤內科專家

簡介:陸道培醫院醫療執行院長、清華大學(醫學院)— 北京陸道培血液病研究院院長

擅長:細胞免疫治療、淋巴瘤、骨髓瘤及白血病等的研究及治療。


星期  
坐診時間:【周一至周五(需提前電話預約)】
  • 醫生履歷
  • 科研榮譽
  • 學術論文
  • 北京醫學院畢業后赴美,后獲得在美行醫許可。在美任住院醫后,以杰出的成績被斯坦福大學醫學中心血液病及腫瘤專科錄取為臨床Fellow,取得血液病及腫瘤專家資格。先后獲得了美國國立衛生研究院(NIH)的兩個獎包括個人的博士后研究獎及醫生科學家獎(KO11)。研究了具有抗腫瘤免疫功能的Cytokine Induced Killer (CIK) Cells,在動物實驗上抗腫瘤功能顯著。后被引入中國應用于臨床治療,是國內最早開展的幾項細胞免疫治療之一。曾應美國國家醫學會邀請在年會上報告個人在美成功奮斗歷程。于2012年被美國消費者協會評選為美國杰出的血液病及腫瘤專家。具有美國血液病專科醫師,腫瘤專科醫生執照以及中國行醫執照。

    于2015年回國,回國后主導了多項工作及研究,現任中國非公醫療協會第一屆常務理事、中國非公立醫療機構協會血液病專業委員會主任委員、中國非公立醫療機構協會生物技術與細胞應用專業委員會常務委員、中國造血干細胞捐獻者資料庫專家委員會委員、中國臨床腫瘤學會(CSCO)抗白血病聯盟專家委員會常務委員、中國抗癌協會第一屆血液病轉化醫學專業委員會常務委員。在細胞免疫治療如CAR-T治療、淋巴瘤、骨髓瘤及白血病等多領域有深入的研究及豐富的臨床經驗。

    5b0781b7ee960.jpg

    Lu, P. H., Negrin, R.S. A novel population of expanded human CD3+, CD56+ cells derived from T cells with potent in vivo antitumor activity in SCID mice.

    J. Immunol. 1994 153;1687.

    Lu, P.H., Negrin, R.S. Cellular immunotherapy following autologous hematopoietic progenitor transplantation.

    Biol Blood Marrow Transplant, 1997, 3(3);113-21.

    Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, Wu YN, Deng ZL, Zhang YL, Liu SH, Wu T, Lu PH, Lu DP, Chang AH, Tong CR.High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.

    Leukemia, 2017 Dec;31(12):2587-2593. doi: 10.1038/leu.2017.145. Epub 2017 May 15.

    Yang Zhang, Fang Wang, Xue Chen, Yu Zhang, Mingyu Wang, Hong Liu, Panxiang Cao, Xiaoli Ma, Tong Wang, Jianping Zhang, Xian Zhang, Peihua Lu#, and Hongxing Liu#.CSF3R mutations are frequently associated with abnormalities of RUNX1, CBFB,CEBPA, and NPM1 genes in acute myeloid leukemia.

    Cancer, 2018 Aug;124(16):3329-3338. doi: 10.1002/cncr.31586. Epub 2018 Jun 22.

    Saleem MS, Aljurf M, Srivastava A, Shamsi T, Lu PH, Hamidieh AA, El Haddad A, Hashmi SK. Challenges in managing graft-versus-host disease in developing countries: a perspective.

    Bone Marrow Transplant, 2018 Sep 20. doi: 10.1038/s41409-018-0333-z. [Epub ahead of print]

    Abstract:

    Lu, P.H. Negrin, R.S. Interleukin-12 promotes the expansion of CD3+CD56+ killer cells derived from CD3+CD56- T cells with enhanced cytotoxicity.

    Blood, 1994, Vol 84, No 10, Suppl: pp289a

    Lu, P.H. Negrin, R.S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in SCID mice.

    Blood, 1993, Vol 82, No 10, Suppl:pp188a (oral presentation at ASH in Dec.1993)

    Lu, P.H. Wang, Z and Negrin, R.S. Functional properties of clonal populations of CD3+CD56+ cells.  

    Blood, 1996, Vol 88, No 10, Suppl:pp42b.

    Lu, P.H. Wang, Z, Mehta, B and Negrin, R.S. Role of IL-12 and IL-15 in the ex vivo expansion, cytotoxicity and cytokine production of human CD3+CD56+ cells derived from T cells.

    Blood, 1996, Vol 88, No 10, Suppl:pp316a.

    Wang, Z, Lu, P.H. Weiner, G, Tso, Jand Negrn, R.S. Anti-CD3 X anti-1D10 bispecific antibody retargets and enhances the cytotoxicity of cytokine induced killer cells.

    Blood, 1996, Vol, No 1,Suppl:pp316a.

    Biping Deng, Alex Hongsheng Chang, Junfang Yang, Jing Pan, Xian Zhang, Yuehui Lin, Yanan Wu, Zhenling Deng, Peihua Lu, Tong Wu, Zhaoli Liu, Chunrong Tong. Safety and efficacy of low dose CD19-CART therapy in 47 cases with relapsed refractory B-cell acute lymphoblastic leukemia(B-ALL).

    ASH, December 3-6, 2016, oral presentation.

    Xian Zhang1*, Xin-An Lu2*, Min Xiong1, Jun-Fang Yang1, Jian-Ping Zhang1, Xiao-Su Zhou1, Ting He2#, Pei-Hua Lu1#, Safety and efficacy of autologous or donor-derived CD19 CAR-T Treatment in relapsed B acute lymphocytic leukemia after Allo-HSCT.

    EBMT, March 18-21,2018, oral presentation.

    Junfang Yang1*, Xin-An Lu2*, Xian Zhang1, Min Xiong1, Jian-Ping Zhang1, Xiao-Su Zhou1, Fei-fei Qi2, Ting He2#, Pei-Hua Lu1#, Comparison of CD19 CAR-T cells with distinct co-stimulatory domains in treatment of B-cell acute lymphoblastic leukemia.

    ASCO, June 1-5,2018, presentation in the Poster Session.

    Junfang Yang, Jianqiang Li, Xian Zhang, Fanyong Lv,  Xiaoling Guo, Qinglong Wang,Lin Wang,Dandan Chen,Xiaosu Zhou, Jinhai Ren, Peihua Lu#, A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia.

    ASH, December 1-4, 2018, oral presentation.

    Xian Zhang, Xin-an Lu, Junfang Yang, Fanyong Lv, Min Xiong, Jianping Zhang, Xiaosu Zhou, Ting He, Peihua Lu#?,Efficacy and Safety of CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphocytic Leukemia (B-cell ALL) in a Large Cohort Including Patients with Extramedullary Disease(EMD), High Leukemia Burden(HLB), BCR-ABL (+) Mutation,TP53 Mutation, and Post-Transplant Relapse.

    ASH, December 1-4, 2018, oral presentation.

  • 截止目前,陸道培醫院已經成功完成560多例C...【詳細】
    造血干細胞移植后40多天的伍先生目前住在陸道...【詳細】
    CAR-T(T細胞嵌合抗原受體)作為一種免疫...【詳細】
     
    中華人民共和國衛生部
    中華骨髓庫
    血液病專科醫協體
    湖北省干細胞庫
    北京赛车开奖结果网址